Company intelligence / Profile preview

M.I.Tech

Pyeongtaek-si, Gyeonggi-do, South Koreami-tech.us ↗

Ownership: Private
Development stage: Commercial

Overview

M.I.Tech is a global leader in the development and manufacturing of innovative gastrointestinal and airway stents. Its flagship product line includes the HANAROSTENT self-expanding metal stent portfolio for GI and airway applications. The company holds major regulatory certifications including CE MDR and FDA approval. Products are distributed in over 58 countries with established commercial presence. Clinical results are not detailed but products have been widely adopted for clinical use.

Therapeutic areas: GastroenterologyPulmonology
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

HANAROSTENT

Commercial

Indications: Gastrointestinal obstruction, Airway obstruction

Partnerships

Boston Scientific – distribution agreement since at least 2015 to sell HANAROSTENT technology in Japan.

Beyond the preview

Go deeper on M.I.Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M.I.Tech.

Explore the full profile